“We’ve had advancements, but we need to go faster,” said ASCO President Howard A. "Skip" Burris III, MD, as he stressed the importance of advancing therapies for better patient outcomes by addressing obstacles to patients’ care. “Access to care, access to clinical trials, and access to information are really key.”
Both the federal government and state officials have implemented policies and safeguards to slow transmission of the virus. Perhaps most troubling in this new environment were the state moratoriums on “elective” surgical procedures.
As I recall the early days of the HIV/AIDS pandemic, what stands out most is its profound human cost and the courage of those who helped our society transcend it. We are in the midst of a time in which the human toll of COVID-19 and the enormity of the path ahead are clear.
The American Society of Clinical Oncology recommends that cancer survivors who have completed their treatment and are under surveillance with no known evidence of disease are to be kept out of care facilities to avoid developing COVID-19.
The authors established a claims-based mechanism for identifying patients with lung cancer with more severe patient-reported cancer-related symptoms who could benefit from engagement with health care programs.
Benchmarking, accountability, bilateralism, and scalability are the 4 parameters critical to successful alternative payment models in oncology, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.